Foundation Medicine Inc., of Cambridge, Mass., reported that interim findings from a phase II study of Boulder, Colo.-based Clovis Oncology Inc.'s rucaparib in patients with relapsed, platinum-sensitive ovarian cancer suggest that Foundation's companion diagnostic can identify both BRCA-mutant patients and non-BRCA-mutant patients who are more likely to benefit from rucaparib than patients who are biomarker negative.